Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients globally. Its portfolio includes AVT02, a high-concentration, low-volume adalimumab formulation biosimilar to Humira, used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, and ulcerative colitis. The company also offers AVT04, a biosimilar to Stelara for psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis; AVT06, a biosimilar to Eylea for neovascular age-related macular degeneration, macular edema, diabetic macular edema, and diabetic retinopathy; AVT03, a biosimilar to Xgeva and Prolia for preventing bone fractures and spinal cord compression in cancer patients and increasing bone mass; and AVT05, a biosimilar to Simponi and Simponi Aria for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Additionally, Alvotech is developing AVT16, a biosimilar to Entyvio for ulcerative colitis and Crohn's disease, and AVT23, a biosimilar to Xolair for allergic asthma and chronic conditions.

Alvotech is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol ALVO. Its shares are traded in US Dollars (USD). The company is headquartered in Luxembourg, but its stock is listed on a US exchange, providing access to American and international investors.

Alvotech operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company focuses on developing and manufacturing biosimilar medicines, which are biologic medical products that are highly similar to already approved reference biologics. As a specialty and generic drug manufacturer, Alvotech targets complex therapeutic areas such as autoimmune diseases, eye disorders, bone conditions, and cancer, offering more affordable alternatives to expensive biologic treatments.

Alvotech is headquartered in Luxembourg, a country in Europe. The company serves patients globally, as indicated in its description summary. Its biosimilar products are developed for international markets, targeting therapeutic areas like autoimmune disorders, eye conditions, bone diseases, and cancer. While the company is based in Luxembourg, its stock is listed on the Nasdaq in the United States, reflecting its global reach and investor base.

Alvotech generates revenue by developing and manufacturing biosimilar medicines, which are lower-cost alternatives to expensive biologic drugs. The company focuses on complex therapeutic areas including autoimmune diseases (e.g., rheumatoid arthritis, Crohn's disease), eye disorders (e.g., age-related macular degeneration), bone conditions (e.g., osteoporosis, cancer-related bone complications), and allergic asthma. Its portfolio includes products like AVT02 (biosimilar to Humira), AVT04 (biosimilar to Stelara), AVT06 (biosimilar to Eylea), AVT03 (biosimilar to Xgeva/Prolia), and AVT05 (biosimilar to Simponi). By offering these biosimilars, Alvotech aims to capture market share from branded biologics, typically at reduced prices, while maintaining profitability through efficient manufacturing and global distribution.